Effect of doxercalciferol (1alfa hydroxyvitamin D2) on PTH, bone turnover and bone mineral density in a hemodialysis patient with persistent secondary hypreparathyroidism post-parathyroidectomy.

PARISI MS; OLIVERI BEATRIZ; SOMOZA J; MAUTALEN C

CLINICAL NEPHROLOGY

DUSTRI-VERLAG DR KARL FEISTLE

Año: 2003 vol. 59 p. 471 - 474

0301-0430

Abstract. The eftleacy and safety of the vitamin D analog, doxerealciferol (lo.—hy- droxyvitamin D2, lo·.D2) in the treatment of secondary liyperpaiathyroidisin in hemo- dialysis patients has been previously re- ported. We report thse eftect of lo-week lrrD2 treatment on rnineral metabolism and bone mineral density (BMD) inahemodialysis patient with persistent secondary liyperpara- tliyroidi.sm post parathyroiclectoiny, resistant to previous ealeitriol treatment. Levels of iPTl—l, bone-specilie alkaline phosphatase and serum type `I collagen C telopeptide were above normal at baseline and were substan- tially decreased with lo.]32 treatment (-92%, -63% and -53%, respectively). BMD in- creased in all areas: total skeleton (+6.5%), lumbar spine (+6.9%) and total femur (+4.3%). The patient showed no hypereal- eemia, and phosphorus levels remained be- tween 3.3 and 6.2 mgfdl.